Latest News about AZN
Recent news which mentions AZN
GNPX Stock: 5 Things to Know as Genprex Rockets Higher
January 03, 2022
From InvestorPlace
Genprex's Lead Cancer Program Scores Second FDA Fast Track Tag For Lung Cancer Setting
January 03, 2022
From Benzinga
Ovid Therapeutics Expands Its Anti-Epileptic Franchise With AstraZeneca Licensing Pact
January 03, 2022
From Benzinga
The Week Ahead In Biotech (Jan 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week
January 02, 2022
From Benzinga
These 3 Stocks Just Hiked Their Dividends: Should You Buy Them?
January 01, 2022
From Motley Fool
Could AstraZeneca Help You Retire a Millionaire?
January 01, 2022
From Motley Fool
3 COVID Stocks to Fight Omicron
December 23, 2021
From Motley Fool
From Benzinga
FDA adds Merck antiviral to COVID-19 tool kit for high-risk adults above 18, amid flurry of positive news on boosters
December 23, 2021
From MarketWatch
Tesla Leads Automobile Stocks to be Among Wednesday's Top Performers
December 23, 2021
From Benzinga
Oil edges higher after ending at nearly 1-month high
December 23, 2021
From MarketWatch
A Large Bet On This Vaccine Stock Rallying More Than 40%
December 23, 2021
From Benzinga
These wild market forecasts have a 50% chance of happening in 2022, says hedge-fund investor
December 23, 2021
From MarketWatch
S&P 500 hints at a run toward all-time highs as futures rise in final session before Christmas
December 23, 2021
From MarketWatch
AstraZeneca says COVID-19 booster effective against omicron in study
December 23, 2021
Tickers
AZN
From MarketWatch
From InvestorPlace
3 Things About Novavax That Smart Investors Know
December 21, 2021
From Motley Fool
What Are the Best Vaccine Stocks to Own in 2022?
December 21, 2021
From Motley Fool
Data suggests boosters essential to avoid omicron infection, and Fauci says best way to protect kids is make sure adults around them are fully vaccinated
December 20, 2021
From MarketWatch
Is Argenx a Good Biotech Stock to Buy for 2022?
December 20, 2021
From Motley Fool
Dr. Francis Collins, National Institutes of Health outgoing director: ‘Nobody was expecting omicron. This one really was a curveball.’
December 20, 2021
From MarketWatch
From Benzinga
Europe stocks slide as COVID worries swamp investors
December 20, 2021
From MarketWatch
The Week Ahead In Biotech (Dec. 19-25): Amgen And Aquestive Regulatory Decisions Key Events Of Holiday-Shortened Week
December 19, 2021
From Benzinga
Is This New Data on Valneva's Less-Effective Booster Concerning?
December 18, 2021
From Motley Fool
A COVID-19 recovery offers low protection against omicron variant but boosters are effective, London study finds
December 17, 2021
From MarketWatch
This New Study Could Give Moderna a Big Advantage in 2022
December 17, 2021
From Motley Fool
Johnson & Johnson's, Sputnik, Sinopharm COVID-19 Vaccines Show Weakness Against Omicron Variant: Study
December 17, 2021
From Benzinga
AstraZeneca's COVID-19 Antibody Effective Against Omicron Variant
December 16, 2021
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.